Lymphoma Information Network - Follicular Non-Hodgkin's Lymphoma
Site Navigation

Follicular Lymphomas

Title Page

Site Map

Adult Lymphoma
Hodgkin's
NHL
DiagnosisNHL TypesAggressiveIndolentB-cell NHLsT-cell NHLsLarge CellTreatmentChemotherapyImmunotherapyTransplantsResources

ChildhoodChildhood HDChildhood NHL

Your Host

 

 

 

 

 

Follicular lymphomas (or more formally speaking, follicular center cell lymphomas with a follicular growth pattern) are one of the more common non-Hodgkin's lymphomas in North America. They afflict almost exclusively adults, particularly the middle-aged and elderly. They are of B-cell lymphocyte origin. Because the small-cleaved cells of follicular lymphomas know how to circulate in the blood, patients usually present with disseminated lymphadenopathy (lymphoma in multiple parts of the body). Nonetheless these lymphomas have a better prognosis than higher grade lymphomas.

Causes

Most cases of follicular lymphoma, especially those rich in small-cleaved cells, have a t(14;18) gene translocation. This results in a rearranged and constitutively over-expressed gene called BCL-2. 

The BCL-2 gene tells the body to produce an inner mitochondrial membrane protein that blocks programmed cell death (apoptosis). Although this protein is produced by an unrearranged BCL-2 gene in much benign (non-cancerous) lymphoid tissue and is present in many lymphomas besides follicular ones, it is not detected in benign, reactive germinal center cells
30.gif (46 bytes)


Follicular Cell Lymphomas: A Breakdown

Follicular lymphomas are divided into 3 types according to the ratio of small-cleaved and large cells:

1. Small-cleaved cell type has less than 20-25% large cells, or
fewer than 5 large cells per high power field. This lymphoma is rich in small-cleaved cells, which know how to voyage in the blood and are often found there as well as in the marrow and liver. Patients nevertheless have a median survival of 7.5-9 years. As in other indolent lymphomas, however, standard chemotherapy cannot secure a protracted remission or cure.

2. Mixed small-cleaved and large cell type has between 20-25% and 50% large cells or between 5 and 15 large cells per high
power field. Though these lymphomas are also indolent (low grade in the Working Formulation), the increased percentage of large cells is associated with a reduced average survival.

3. Large cell type has more than 50% large cells, or more than 15 large cells per high power field. Large cell lymphomas with a follicular growth pattern are uncommon, and the nodularity can be hard to perceive. These lymphomas are the only intermediate grade follicular lymphomas - they are classified as indolent but their aggressive nature is noted by NCI.

Treatment

Treatment options depend on the stage and grade of the disease. The infrequent adult patients with early-stage disease may be treated with local radiation, with or without chemotherapy. Patients with more advanced but low-grade disease may remain untreated as long as no symptoms or lymphoma-related organ compromise are present (watch and wait). When treatment becomes necessary, the options include:

1) single-agent alkylator chemotherapy; 2) low-intensity combined chemotherapy without an anthracycline; 3) whole-body irradiation. Large-cell follicular lymphoma is classified as an intermediate-grade lymphoma, and the patients may benefit from the inclusion of an anthracycline in their chemotherapy.  Immunotherapy and Monoclonal Antibody Therapy specifically has shown promise in the treatment of follicular lymphomas recently.   This includes drugs such as Rituxan (rituximab / MabThera) and possibly others like Bexxar and Zevalin.

T-cell immunotherapy

Cytotoxic T-lymphocytes (CTL), also known as “killer” T-cells, are also an important component of the immune system and specifically directing these immune cells to fight lymphoma cells by gene therapy is an emerging technology.  Genetically modified CTL can recognize lymphoma cells like a monoclonal antibody, but then attack the lymphoma cells like a “killer” T-cell.  At the Fred Hutchinson Cancer Research Center in Seattle, lymphoma researchers have started using this gene therapy approach following chemotherapy to treat patients with relapsed follicular non-Hodgkin’s lymphoma.  For more information about this study, call +1-206-667-5184 or go to http://www.fhcrc.org/cancer_info/studies/1503.html

Further Reading

Non-Hodgkin's Lymphomas, Peter M. Mauch (Editor), James O. Armitage (Editor), et al., 2004.
  • Section IV: Pathology, Biology, Clinical Evaluation, and Treatment Section
    • Chapter 24: Follicular Lymphoma
Living With Lymphoma, Elizabeth Adler, Oct. 2005
  • Chapter 10: Lymphoma Classification and Staging
    Follicular Lymphomas, pp. 298-301

Web Sites

Survivor Sites

  • Robert Miller is a survivor of follicular and diffuse lymphoma with articles on his site.

Mailing Lists


Reference Sources


Non-Hodgkin's Lymphoma Information Pages:

    Non-Hodgkin's Lymphomas
    Non-Hodgkin's Lymphoma: Diagnosis
    Non-Hodgkin's Lymphoma: Aggressive Lymphomas
    Non-Hodgkin's Lymphoma: Indolent Lymphomas
    Non-Hodgkin's Lymphoma: Treatment
    Non-Hodgkin's Lymphoma: Resources
    Bone Marrow and Stem Cell Transplants

Childhood Lymphoma Information Pages:

    Childhood Lymphoma
    Childhood Non-Hodgkin's Lymphoma

Home - Gateway to Support and More

    The Lymphoma Information Network


This page is a work in progress - if you have more complete information, references, or other information please contact the author. The author is not in the medical field and does not warrant the correctness of the material on this page or the sites linked - please take online information and consult with your own medical team to make informed decisions.

Copyright © 1998-2006 Lymphoma Information Network - All Rights Reserved
http://www.LymphomaInfo.net/
Updated June 1, 2006